Previous close | 89.51 |
Open | 92.36 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 89.12 - 89.48 |
52-week range | 84.53 - 119.56 |
Volume | |
Avg. volume | 63,990 |
Market cap | N/A |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | 0.16 |
EPS (TTM) | 5.59 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Merck & Co., Inc. ( NYSE:MRK ) just released its quarterly report and things are looking bullish. The company beat...
Shares of Merck & Company (MRK) are trading higher early Thursday after the pharmaceutical giant posted robust sales results in the first quarter, leading the pharmaceutical giant to raise its 2024 outlook. The company's performance was driven by strong demand for its cancer drug Keytruda. Yahoo Finance's Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance. This post was written by Angel Smith
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...